Drug-Drug Interaction (DDI) prediction is one of the most critical issues in drug development and health. Proposing appropriate computational methods for predicting unknown DDI with high precision is challenging. We proposed "NDD: Neural network-based method for drug-drug interaction prediction" for predicting unknown DDIs using various information about drugs. Multiple drug similarities based on drug substructure, target, side effect, off-label side effect, pathway, transporter, and indication data are calculated. At first, NDD uses a heuristic similarity selection process and then integrates the selected similarities with a nonlinear similarity fusion method to achieve high-level features. Afterward, it uses a neural network for interaction prediction. The similarity selection and similarity integration parts of NDD have been proposed in previous studies of other problems. Our novelty is to combine these parts with new neural network architecture and apply these approaches in the context of DDI prediction. We compared NDD with six machine learning classifiers and six state-of-the-art graph-based methods on three benchmark datasets. NDD achieved superior performance in cross-validation with AUPR ranging from 0.830 to 0.947, AUC from 0.954 to 0.994 and F-measure from 0.772 to 0.902. Moreover, cumulative evidence in case studies on numerous drug pairs, further confirm the ability of NDD to predict unknown DDIs. The evaluations corroborate that NDD is an efficient method for predicting unknown DDIs. The data and implementation of NDD are available at https://github.com/nrohani/NDD.

Background: Polypharmacy is a type of treatment that involves the concurrent use of multiple medications. Drugs may interact when they are used simultaneously. So, understanding and mitigating polypharmacy side effects are critical for patient safety and health. Since the known polypharmacy side effects are rare and they are not detected in clinical trials, computational methods are developed to model polypharmacy side effects. Results: We propose a neural network-based method for polypharmacy side effects prediction (NNPS) by using novel feature vectors based on mono side effects, and drug–protein interaction information. The proposed method is fast and efficient which allows the investigation of large numbers of polypharmacy side effects. Our novelty is defining new feature vectors for drugs and combining them with a neural network architecture to apply for the context of polypharmacy side effects prediction. We compare NNPS on a benchmark dataset to predict 964 polypharmacy side effects against 5 well-established methods and show that NNPS achieves better results than the results of all 5 methods in terms of accuracy, complexity, and running time speed. NNPS outperforms about 9.2% in Area Under the Receiver-Operating Characteristic, 12.8% in Area Under the Precision–Recall Curve, 8.6% in F-score, 10.3% in Accuracy, and 18.7% in Matthews Correlation Coefficient with 5-fold cross-validation against the best algorithm among other well-established methods (Decagon method). Also, the running time of the Decagon method which is 15 days for one fold of cross-validation is reduced to 8 h by the NNPS method. Conclusions: The performance of NNPS is benchmarked against 5 well-known methods, Decagon, Concatenated drug features, Deep Walk, DEDICOM, and RESCAL, for 964 polypharmacy side effects. We adopt the 5-fold cross-validation for 50 iterations and use the average of the results to assess the performance of the NNPS method. The evaluation of the NNPS against five well-known methods, in terms of accuracy, complexity, and running time speed shows the performance of the presented method for an essential and challenging problem in pharmacology. Datasets and code for NNPS algorithm are freely accessible at https://github.com/raziyehmasumshah/NNPS.

Inferring Gene Regulatory Networks (GRNs) from gene expression data is a major challenge in systems biology. The Path Consistency (PC) algorithm is one of the popular methods in this field. However, as an order dependent algorithm, PC algorithm is not robust because it achieves different network topologies if gene orders are permuted. In addition, the performance of this algorithm depends on the threshold value used for independence tests. Consequently, selecting suitable sequential ordering of nodes and an appropriate threshold value for the inputs of PC algorithm are challenges to infer a good GRN. In this work, we propose a heuristic algorithm, namely SORDER, to find a suitable sequential ordering of nodes. Based on the SORDER algorithm and a suitable interval threshold for Conditional Mutual Information (CMI) tests, a network inference method, namely the Consensus Network (CN), has been developed. In the proposed method, for each edge of the complete graph, a weighted value is defined. This value is considered as the reliability value of dependency between two nodes. The final inferred network, obtained using the CN algorithm, contains edges with a reliability value of dependency of more than a defined threshold. The effectiveness of this method is benchmarked through several networks from the DREAM challenge and the widely used SOS DNA repair network in Escherichia coli. The results indicate that the CN algorithm is suitable for learning GRNs and it considerably improves the precision of network inference. The source of data sets and codes are available at http://bs.ipm.ir/softwares/CN.

Motivation: Because unanticipated drug–drug interactions (DDIs) can result in severe bodily harm, identifying the adverse effects of polypharmacy is one of the most important tasks in human health. Over the past few decades, computational methods for predicting the adverse effects of polypharmacy have been developed. Results: This article presents DPSP, a framework for predicting polypharmacy side effects based on the construction of novel drug features and the application of a deep neural network to predict DDIs. In the first step, a variety of drug information is evaluated, and a feature extraction method and the Jaccard similarity are used to determine similarities between two drugs. By combining these similarities, a novel feature vector is generated for each drug. In the second step, the method predicts DDIs for specific DDI events using a multimodal framework and drug feature vectors. On three benchmark datasets, the performance of DPSP is measured by comparing its results to those of several well-known methods, such as GNN–DDI, MSTE, MDF–SA–DDI, NNPS, DDIMDL, DNN, DeepDDI, KNN, LR, and RF. DPSP outperforms these classification methods based on a variety of classification metrics. The results indicate that the use of diverse drug information is effective and efficient for identifying DDI adverse effects. Availability and implementation: The source code and datasets are available at https://github.com/raziyehmasumshah/DPSP.

Background: Predicting the response of cancer cell lines to specific drugs is an essential problem in personalized medicine. Since drug response is closely associated with genomic information in cancer cells, some large panels of several hundred human cancer cell lines are organized with genomic and pharmacogenomic data. Although several methods have been developed to predict the drug response, there are many challenges in achieving accurate predictions. This study proposes a novel feature selection-based method, named Auto-HMM-LMF, to predict cell line-drug associations accurately. Because of the vast dimensions of the feature space for predicting the drug response, Auto-HMM-LMF focuses on the feature selection issue for exploiting a subset of inputs with a significant contribution. Results: This research introduces a novel method for feature selection of mutation data based on signature assignments and hidden Markov models. Also, we use the autoencoder models for feature selection of gene expression and copy number variation data. After selecting features, the logistic matrix factorization model is applied to predict drug response values. Besides, by comparing to one of the most powerful feature selection methods, the ensemble feature selection method (EFS), we showed that the performance of the predictive model based on selected features introduced in this paper is much better for drug response prediction. Two datasets, the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) are used to indicate the efficiency of the proposed method across unseen patient cell-line. Evaluation of the proposed model showed that Auto-HMM-LMF could improve the accuracy of the results of the state-of-the-art algorithms, and it can find useful features for the logistic matrix factorization method. Conclusions: We depicted an application of Auto-HMM-LMF in exploring the new candidate drugs for head and neck cancer that showed the proposed method is useful in drug repositioning and personalized medicine. The source code of Auto-HMM-LMF method is available in https://github.com/emdadi/Auto-HMM-LMF.